- Home
- BNL vs NAMS Comparison
BNL vs NAMS Comparison
Compare BNL & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNL
- NAMS
- Stock Information
- Founded
- BNL 2007
- NAMS 2019
- Country
- BNL United States
- NAMS Netherlands
- Employees
- BNL N/A
- NAMS N/A
- Industry
- BNL Real Estate Investment Trusts
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BNL Real Estate
- NAMS Health Care
- Exchange
- BNL Nasdaq
- NAMS Nasdaq
- Market Cap
- BNL 3.0B
- NAMS 2.5B
- IPO Year
- BNL 2020
- NAMS N/A
- Fundamental
- Price
- BNL $16.20
- NAMS $18.18
- Analyst Decision
- BNL Hold
- NAMS Strong Buy
- Analyst Count
- BNL 5
- NAMS 8
- Target Price
- BNL $18.40
- NAMS $42.88
- AVG Volume (30 Days)
- BNL 1.5M
- NAMS 1.0M
- Earning Date
- BNL 07-29-2025
- NAMS 08-06-2025
- Dividend Yield
- BNL 7.10%
- NAMS N/A
- EPS Growth
- BNL N/A
- NAMS N/A
- EPS
- BNL 0.60
- NAMS N/A
- Revenue
- BNL $435,124,000.00
- NAMS $47,140,000.00
- Revenue This Year
- BNL $4.15
- NAMS N/A
- Revenue Next Year
- BNL $5.26
- NAMS N/A
- P/E Ratio
- BNL $27.20
- NAMS N/A
- Revenue Growth
- BNL 1.37
- NAMS 586.97
- 52 Week Low
- BNL $13.96
- NAMS $14.06
- 52 Week High
- BNL $19.15
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BNL 50.98
- NAMS 42.76
- Support Level
- BNL $15.66
- NAMS $17.67
- Resistance Level
- BNL $16.38
- NAMS $18.97
- Average True Range (ATR)
- BNL 0.29
- NAMS 1.15
- MACD
- BNL -0.01
- NAMS -0.17
- Stochastic Oscillator
- BNL 55.67
- NAMS 8.12
About BNL Broadstone Net Lease Inc.
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.